Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Inclusion Criteria:

- Patients in first relapse or primary induction failure CD20 positive B-cell
leukemia/lymphoma including:

- Diffuse Large B-Cell Lymphoma

- Burkitt Lymphoma

- High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)

- Primary mediastinal B-cell lymphoma (PMBL)

- CD20+ B-lymphoblastic lymphoma

- Follicular lymphoma, Grade III

- Karnofsky ≥ 60% for patients > 16 years of age and

- Lansky ≥ 60 for patients ≤ 16 years of age.

- Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry
onto this study.

- Patients may not have received prior therapy with obinutuzumab (GA101)

- Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local
palliative XRT (small port); > 6 months must have elapsed if prior craniospinal
XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other
substantial bone marrow radiation.

- Steroids: Patients may have received prior steroid treatment, but not started
greater than 7 days prior to initiation of protocol therapy.

- Adequate organ function.

Exclusion Criteria:

- Patients with newly diagnosed, previously untreated B-NHL.

- Known congenital or acquired immune deficiency.

- Prior solid organ transplantation.

- Prior allogeneic stem cell transplant within 60 days or active acute
Graft-vs-Host-Disease (GVHD) grade 3 or higher.

- History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies

- Uncontrolled hepatitis B and/or C infection